CryoPort (NASDAQ:CYRX) Now Covered by Analysts at Craig Hallum

Craig Hallum started coverage on shares of CryoPort (NASDAQ:CYRX) in a research report report published on Monday morning,Benzinga reports. The brokerage issued a buy rating and a $15.00 target price on the stock.

CYRX has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Friday. Needham & Company LLC lifted their price objective on shares of CryoPort from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Finally, Wall Street Zen downgraded shares of CryoPort from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.15.

CryoPort Stock Up 0.9%

NASDAQ:CYRX opened at $7.89 on Monday. CryoPort has a 12-month low of $4.63 and a 12-month high of $11.45. The firm has a market capitalization of $393.40 million, a P/E ratio of 5.98 and a beta of 1.69. The stock’s fifty day simple moving average is $8.71 and its 200-day simple moving average is $9.28.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The company had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. As a group, equities research analysts expect that CryoPort will post -0.99 earnings per share for the current year.

Insider Buying and Selling at CryoPort

In other news, CFO Robert Stefanovich sold 38,700 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $7.76, for a total value of $300,312.00. Following the sale, the chief financial officer directly owned 255,701 shares in the company, valued at $1,984,239.76. The trade was a 13.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Mark W. Sawicki sold 3,235 shares of the company’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total value of $25,880.00. Following the transaction, the insider directly owned 103,697 shares of the company’s stock, valued at $829,576. This represents a 3.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 59,939 shares of company stock valued at $471,183 in the last 90 days. 10.10% of the stock is currently owned by company insiders.

Institutional Trading of CryoPort

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. grew its position in CryoPort by 37.4% in the third quarter. Assenagon Asset Management S.A. now owns 1,498,774 shares of the company’s stock valued at $14,208,000 after purchasing an additional 408,263 shares in the last quarter. SG Americas Securities LLC lifted its position in CryoPort by 663.2% during the 3rd quarter. SG Americas Securities LLC now owns 127,280 shares of the company’s stock worth $1,207,000 after buying an additional 110,602 shares in the last quarter. Thematics Asset Management boosted its stake in shares of CryoPort by 12.8% during the 2nd quarter. Thematics Asset Management now owns 1,914,885 shares of the company’s stock worth $14,285,000 after buying an additional 216,937 shares during the last quarter. Mak Capital One LLC acquired a new position in shares of CryoPort during the 3rd quarter worth about $7,756,000. Finally, Kennedy Capital Management LLC bought a new position in shares of CryoPort in the 2nd quarter valued at about $4,084,000. 92.90% of the stock is currently owned by institutional investors and hedge funds.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.